ArticleAdvanced healthcare materials2022
Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold.
Article in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Gel-Based Drug Delivery Platforms: A Critical, Mechanistic Review of Design, Cross-Linking, and Disease-Specific Translation (2010-2026).Gels (Basel, Switzerland) · 2026Review
- Carbohydrate-Based Hydrogels: Weaving Nature's Versatility into Biomedical Innovation.International journal of nanomedicine · 2026Review
- Development of a single-dose Q fever vaccine with an injectable nanoparticle-loaded hydrogel: effect of sustained co-delivery of antigen and adjuvant.Drug delivery · 2025Article
- Use of the Slow-Delivery Platform, VacSIM, Shapes the Host Immune Response to Increase Protection Against Influenza Infection.Viruses · 2025Article
- Sustained exposure to multivalent antigen-decorated nanoparticles generates broad anti-coronavirus responses.Matter · 2025Article
- Hydrogel applications: a promising frontier in pneumonia therapy.Frontiers in bioengineering and biotechnology · 2025Review
- Beyond Needles: Immunomodulatory Hydrogel-Guided Vaccine Delivery Systems.Gels (Basel, Switzerland) · 2024Review
- Tailoring biomaterials for vaccine delivery.Journal of nanobiotechnology · 2024Review
- Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants.Journal of nanobiotechnology · 2024Article
- The quest for nanoparticle-powered vaccines in cancer immunotherapy.Journal of nanobiotechnology · 2024Review
- Biodegradable scaffolds for enhancing vaccine delivery.Bioengineering & translational medicine · 2023Article
- Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine.Advanced healthcare materials · 2023Article
- Review
- Nanosponges: An overlooked promising strategy to combat SARS-CoV-2.Drug discovery today · 2022Review
- An in situ hydrogel-mediated chemo-immunometabolic cancer therapy.Nature communications · 2022Article
- Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold.Advanced healthcare materials · 2022Article
- Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
The receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein that mediates viral entry into host cells is a good candidate immunogen for vaccine development against coronavirus disease 2019 (COVID-19). Because of its small size, most preclinical and early clinical efforts have focused on multimerizing RBD on various formats of nanoparticles to increase its immunogenicity. Using an easily administered injectable hydrogel scaffold that is rationally designed for enhanced retainment of RBD, an alternative and facile approach for boosting RBD immunogenicity in mice is demonstrated. Prolonged delivery of poly (I:C) adjuvanted RBD by the hydrogel scaffold results in sustained exposure to lymphoid tissues, which elicits serum IgG titers comparable to those induced by three bolus injections, but more long-lasting and polarized toward T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.